New York, New York, United States Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the most popular fund investment industries, there is Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Passage Bio.
The usual cause for the fund is to invest in rounds with more than 10 partakers. Despite the Highline Capital Management, startups are often financed by Vivo Capital, Versant Ventures, OrbiMed. The meaningful sponsors for the fund in investment in the same round are Logos Capital, Vivo Capital, Versant Ventures.
The top activity for fund was in 2019. The fund is generally included in less than 2 deals every year. Deals in the range of more than 100 millions dollars are the general things for fund.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Accelerant Venture Capital | - |
| ACCIONA I'MNOVATION | Alcobendas, Madrid, Spain |
| Adjuvo | England, London, United Kingdom |
| Altria | Richmond, United States, Virginia |
| Ascot Underwriting | England, London, United Kingdom |
| Chapman Office | England, London, United Kingdom |
| Effective Investments | Kyiv, Ukraine, Київська міська громада |
| Fastlane Ventures | Cyprus, Limassol |
| Gansu Xuanyuan Pharmaceutical Development | - |
| Helios Capital | New York, New York, United States |
| Kopf &Capital | Baden-Wurttemberg, Germany, Mannheim |
| Massachusetts Clean Energy Center | Boston, Massachusetts, United States |
| Qualcomm Robotics Accelerator | California, San Diego, United States |
| Red Kite Mine Finance | England, London, United Kingdom |
| TD Investment | Hyogo Prefecture, Japan, Kobe |
| TechnoCap | Canada, Montréal, Quebec |
| Winston Partners | Arlington, United States, Virginia |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Proscia | $9M | 11 Jan 2024 | Philadelphia, Pennsylvania, United States | ||
Proscia | $36M | 03 Jun 2022 | Philadelphia, Pennsylvania, United States | ||
Strata Oncology | $90M | 28 Jul 2021 | Ann Arbor, Michigan, United States | ||
| $56M | 28 Oct 2020 | San Diego, California, United States | |||
Passage Bio | $110M | 04 Sep 2019 | Philadelphia, Pennsylvania, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Proscia | $9M | 11 Jan 2024 | Philadelphia, Pennsylvania, United States | ||
Proscia | $36M | 03 Jun 2022 | Philadelphia, Pennsylvania, United States | ||
Strata Oncology | $90M | 28 Jul 2021 | Ann Arbor, Michigan, United States | ||
| $56M | 28 Oct 2020 | San Diego, California, United States | |||
Passage Bio | $110M | 04 Sep 2019 | Philadelphia, Pennsylvania, United States |
